A Phase 3 interventional study of Ziltivekimab B and Ziltivekimab C in Cardiovascular Risk, Chronic Kidney Disease and Inflammation, sponsored by Novo Nordisk A/S. Completed at 1,073 sites in 38 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-28.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Renal Insufficiency, Chronic by Novo Nordisk A/S — 5 open to participants now, 6 under way, 1 of them phase 3. Renal Insufficiency, Chronic · Novo Nordisk A/S.
Among the 29 studies in Renal Insufficiency, Chronic by Novo Nordisk A/S, this one has the largest enrollment of the 18 interventional ones that give a count, is one of 4 that started in 2021, is one of 5 in phase 3, and was the 13th registered.
3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.
Browse Renal Insufficiency, Chronic studies →5 of the 29 studies in Renal Insufficiency, Chronic by Novo Nordisk A/S are open now, in 12 countries. Recruiting first, the newest first:
Novo Nordisk A/S · Sites in China
Ages 18+
Novo Nordisk A/S · Sites in United States, Argentina, Australia and 11 more countries
Ages 18+
Novo Nordisk A/S · Sites in Korea, Republic of
Ages 19+
Novo Nordisk A/S · Sites in United States, Brazil, China and 7 more countries
Ages 18+
Novo Nordisk A/S · Sites in Germany
Ages 18–75
By country, each count listing its studies:
Of the 435 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 111 (26%) stop at 75 or younger; 45 take children under 18; 80 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 4 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 6,385 is above the median of 73 across 2,162 interventional studies indexed under Renal Insufficiency, Chronic.
Median enrollment 128 across the 18 interventional studies, 1,500 across the 11 observational. Of the 22 that completed or were terminated, 6 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
1 of the studies in Renal Insufficiency, Chronic by Novo Nordisk A/S that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07808788Novo Nordisk A/SA Research Study Looking Into How a Single Dose of the Medicine NNC0537-1482 Moves Through the Body of Participants With Normal or Reduced Kidney Function | 2027-07-06 |
Add it to your calendar (.ics) → With an account.
Among the 29 studies in Renal Insufficiency, Chronic by Novo Nordisk A/S, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is conducted to see if ziltivekimab reduces the risk of having cardiovascular events (for example heart attack and stroke) in people with cardiovascular disease, chronic kidney disease and inflammation.
Participants will either get ziltivekimab (active medicine) or placebo (a dummy medicine which has no effect on the body). This is known as the study medicine. Which treatment participants get is decided by chance. Participants chance of getting ziltivekimab or placebo is the same.
Ziltivekimab is not yet approved in any country or region in the world. It is a new medicine doctors cannot prescribe.
Participants will get the study medicine in a pre filled syringe. Participants will need to use the pre filled syringe to inject the study medicine into a skinfold once-monthly.
The study is expected to last for up to 4 years. Participants will have up to 20 clinic visits. Participants will have blood and urine samples taken at most of the clinic visits.
Participants will have their heart examined using sound waves (echocardiography) and electrodes (electrocardiogram).
Women cannot take part if pregnant, breast-feeding or planning to get pregnant during the study period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Chronic kidney disease defined by one of the below:
Evidence of atherosclerotic cardiovascular disease (ASCVD) by one or more of the following:
a) Coronary heart disease defined as at least one of the following: i. Documented history of MI ii. Prior coronary revascularisation procedure iii. greater than or equal to 50% stenosis in major epicardial coronary artery documented by cardiac catheterisation or CT coronary angiography b) Cerebrovascular disease defined as at least one of the following: i. Prior stroke of atherosclerotic origin ii. Prior carotid artery revascularisation procedure iii. greater than or equal to 50% stenosis in carotid artery documented by X-ray angiography, MR angiography, CT angiography or Doppler ultrasound.
c) Symptomatic peripheral artery disease (PAD) defined as at least one of the following: i. Intermittent claudication with an ankle-brachial index (ABI) below or equal to 0.90 at rest ii. Intermittent claudication with a greater than or equal to 50% stenosis in peripheral artery (excluding carotid) documented by X-ray angiography, MR angiography, CT angiography or Doppler ultrasound iii. Prior peripheral artery (excluding carotid) revascularisation procedure iv. Lower extremity amputation at or above ankle due to atherosclerotic disease (excluding e.g. trauma or osteomyelitis).
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive Ziltivekimab B or Ziltivekimab C subcutaneously once monthly for up to 4 years.
Drug: Ziltivekimab B · Drug: Ziltivekimab C
Participants will receive either placebo (Ziltivekimab B) or placebo (Ziltivekimab C) subcutaneously once monthly for up to 4 years.
Drug: Placebo (Ziltivekimab B) · Drug: Placebo (Ziltivekimab C)
Administered subcutaneously (s.c., under skin) once-monthly added to standard of care.
Administered subcutaneously (s.c., under skin) once-monthly added to standard of care.
Administered subcutaneously (s.c., under skin) once-monthly added to standard of care.
Administered subcutaneously (s.c., under skin) once-monthly added to standard of care.
Time to first occurrence of 3-point Major Adverse Cardiovascular Event (MACE), a composite endpoint consisting of: Cardiovascular (CV) death, non-fatal Myocardial Infarction (MI) and non-fatal stroke
Months
Time frame: From randomisation (month 0) to end-of-study (up to 48 months)
Time to first occurrence of expanded MACE, a composite endpoint consisting of: CV death, non-fatal MI, non-fatal stroke and hospitalisation for unstable angina pectoris requiring urgent coronary revascularisation
Months
Time frame: From randomisation (month 0) to end-of-study (up to 48 months)
Number of heart failure hospitalisations or urgent heart failure visits or CV deaths
Count
Time frame: From randomisation (month 0) to end-of-study (up to 48 months)
Time to first occurrence of a composite kidney endpoint consisting of: CV death, onset of persistent atleast 40 percent (%) reduction in eGFR (CKD-epidemiology collaboration [CKD-EPI]) compared with baseline, kidney failure
Months
Time frame: From randomisation (month 0) to end-of-study (up to 48 months)
Time to occurrence of all-cause mortality
Months
Time frame: From randomisation (month 0) to end-of-study (up to 48 months)
Time to first occurrence of each of the individual components of the expanded MACE endpoint and the kidney composite endpoint.
Months
Time frame: From randomisation (month 0) to end-of-study (up to 48 months).
Time to first occurrence of MI (fatal and non-fatal).
Months
Time frame: From randomisation (month 0) to end-of-study (up to 48 months).
Time to first occurrence of stroke (fatal and non-fatal).
Months
Time frame: From randomisation (month 0) to end-of-study (up to 48 months).
Time to first occurrence of a composite MACE endpoint consisting of: all-cause mortality, non-fatal MI and non-fatal stroke
Months
Time frame: From randomisation (month 0) to end-of-study (up to 48 months).
Time to first occurrence of a 4-component kidney endpoint consisting of: onset of persistent at least 40% reduction in eGFR (CKD-EPI) compared with baseline, kidney failure
Months
Time frame: From randomisation (month 0) to end-of-study (up to 48 months).
Time to first occurrence of coronary revascularisation
Months
Time frame: From randomisation (month 0) to end-of-study (up to 48 months).
Change in Urinary Abumin-to-Ceatinine ratio (UACR).
Percentage
Time frame: From randomisation (month 0) to 2 years (24 months).
Change in eGFR (CKD-EPI))
mL/min/1.73 m\^2
Time frame: From randomisation (month 0) to 2 years (24 months)
Annual rate of change in eGFR (CKD-EPI) (total eGFR slope)
mL/min/1.73 m\^2/ year
Time frame: From randomisation (month 0) to end-of-study (up to 48 months).
Change in high-sensitivity C-reactive protein (hs-CRP)
Percentage
Time frame: From randomisation (month 0) to 2 years (24 months
Change in N-terminal-pro-brain natriuretic peptide ( NT-pro-BNP)
Percentage
Time frame: From randomisation (month 0) to 2 years (24 months)
Change in left ventricular ejection fraction (LVEF)
Percentage
Time frame: From randomisation (month 0) to 2 years (24 months)
Number of events of atrial fibrillation
Count
Time frame: From randomisation (month 0) to end-of-study (up to 48 months).
Change in haemoglobin
Grams per deciliter (g/dL)
Time frame: From randomisation (month 0) to 2 years (24 months)
Number of hospitalisations with infection as primary cause or death due to infection.
Count
Time frame: From randomisation (month 0) to end-of-study (up to 48 months).
Change in Short Form 36 (SF-36) Physical Component Score (PCS)
Score on scale
Time frame: From randomisation (month 0) to 2 years (24 months)
Showing the first 100 of 1,073 sites across 38 countries. Choose a country and city above to see the rest.
Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Data sharing details ↗ · novonordisk-trials.com
Ran from Aug 2021 to primary completion in Jun 2026, 57 months.
Of 104 industry-sponsored phase 3 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 49. This study's 57 months is above that.
Counting every sponsor, half of 145 studies reached it within 32 months; a quarter within 19 and three quarters within 54.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ziltivekimab
Renal Insufficiency, Chronic →